Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX Operating Cash Flow
Cash generated by the company's core business operations during the period.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
Operating Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Operating cash flow grows, but more slowly than its trailing trend
Q3 FY2026 operating cash flow of $81.74M (cash outflow) rose 26.3% year over year, behind the +41.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 5.3% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.
Context
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +26.3% toward the trailing-twelve-month pace of +41.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (249.07M) USD
- Year-over-year change
- -89.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (249.07M) | -89.0% |
| FY2024 | 2024-12-31 | (131.76M) | -18.6% |
| FY2023 | 2023-12-31 | (111.14M) | +39.9% |
| FY2022 | 2022-12-31 | (185.04M) | -48.6% |
| FY2021 | 2021-12-31 | (124.55M) | — |
Operating Cash Flow vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's LTM Sep 2026 operating cash flow of $322.69M is the 4th largest of the 10 companies compared; the peer median is $71.26M.
- Its year-over-year change of +41.4% is the 2nd highest of 10, against a peer median of +3.4%.
- Over three fiscal years its annual growth of +10.4% compares with a peer median of +20.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.07B | +67.4% | +32.1% | 28.8% | |
| LTM Jun 2026 | $434.04M | +24.1% | +19.0% | 12043.3% | |
| LTM Sep 2026 | $356.1M | +41.3% | +41.5% | — | |
| LTM Sep 2026 | $322.69M | +41.4% | +10.4% | — | |
| LTM Jun 2026 | $194.3M | +3.4% | — | 17.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $193.4M | -3.0% | +21.6% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $80.3M | +19.0% | +199.9% | 401.5% |
| LTM Jun 2026 | $71.26M | -40.9% | -7.1% | 9.2% | |
| LTM Dec 2025 | $34.08M | -4.3% | +17.2% | — | |
| LTM Jun 2026 | $19.91M | -89.4% | -26.0% | 2.4% | |
| Peer median (excluding PRAX) | $71.26M | +3.4% | +20.3% | 22.9% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| Deferred Income Tax | 2.09M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.69M | 28.59M | 24.86M | 41.36M | 33.94M |
| Change in Working Capital | 16.13M | (1.78M) | (13.03M) | 10.92M | 22.68M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.27M | 3.89M | (8.86M) | 6.71M | 12.1M |
| Other Working Capital | 8.87M | (5.67M) | (4.17M) | 4.21M | 10.58M |
| Other Non-Cash Items | 1.41M | 1.76M | (121K) | (1.58M) | (2.56M) |
| Operating Cash Flow | (124.55M) | (185.04M) | (111.14M) | (131.76M) | (249.07M) |
| Capital Expenditures | (1.05M) | (444K) | (50K) | 0 | (56K) |
| Acquisitions (Net) | 139.47M | (97.33M) | 0 | 0 | 0 |
| Purchases of Investments | (164.17M) | (83.02M) | 0 | (371.52M) | (623.81M) |
| Sales of Investments | 24.7M | 180.36M | 39M | 123.03M | 312.72M |
| Other Investing Activities | (139.47M) | 97.33M | 0 | 0 | 0 |
| Investing Cash Flow | (140.52M) | 96.89M | 38.95M | (248.49M) | (311.15M) |
| Debt Repayment | (763K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 105.71M | 9.56M | 91.59M | 512M | 704.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.64M | 904K | 279K | 2.33M | (2.09M) |
| Financing Cash Flow | 107.59M | 10.47M | 91.87M | 514.32M | 702.17M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (157.49M) | (77.69M) | 19.69M | 134.07M | 141.96M |
| Free Cash Flow | (125.6M) | (185.49M) | (111.19M) | (131.76M) | (249.12M) |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.